GWS
VNDA icon

Glassman Wealth Services’s Vanda Pharmaceuticals VNDA Stock Holding History

Glassman Wealth Services’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-340
Closed -$1.44K – 1767
2023
Q4 		$1.44K Buy
340
+216
+174% +$872 ﹤0.01% 1442
2023
Q3 		$536 Sell
124
-53
-30% -$294 ﹤0.01% 1717
2023
Q2 		$1.17K Buy
177
+3
+2% +$19 ﹤0.01% 1398
2023
Q1 		$1.18K Buy
174
+125
+255% +$879 ﹤0.01% 1379
2022
Q4 		$362 Buy
+49
New +$477 ﹤0.01% 1686

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Glassman Wealth Services's VNDA Position: Q1 2024 in Review

Glassman Wealth Services sold out of Vanda Pharmaceuticals (VNDA) in Q1 2024, closing a stake of 340 shares — an estimated $1.44K sold.

Glassman Wealth Services first reported a position in VNDA in Q4 2022 and held it in 5 quarters. The position peaked at $1.44K in Q4 2023. 144 funds tracked by Wall St. Rank hold VNDA as of Q1 2024.

  • Glassman Wealth Services reported no remaining Vanda Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Glassman Wealth Services sold 340 Vanda Pharmaceuticals shares in Q1 2024, an estimated $1.44K.
  • Glassman Wealth Services first reported a position in Vanda Pharmaceuticals in Q4 2022 and held it in 5 quarters.
  • Glassman Wealth Services's Vanda Pharmaceuticals position peaked at $1.44K in Q4 2023.
  • 144 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2024.

Based on Glassman Wealth Services's 13F filing for Q1 2024, filed 3 May 2024.